News Related to Bladder-Intact Survival

Related coverage linked through entity extraction aliases.

ctDNA and urine DNA testing may help select bladder-sparing treatment in muscle-invasive bladder cancer

Apr 15, 2026

Studies in muscle-invasive bladder cancer found ctDNA predicted metastatic risk after bladder-sparing treatment, while urine tumor DNA was more sensitive for residual bladder disease. Data from RETAIN-2 and a PNAS study support molecular testing to help select patients for bladder preservation.

New Molecular Testing May Help Bladder Cancer Patients Avoid Surgery

Feb 25, 2026

Ultrasensitive testing of tumor DNA in blood and urine may identify muscle-invasive bladder cancer patients who can safely forgo radical cystectomy, with 69% achieving 3-year bladder-intact survival after systemic therapy.